Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical...
Saved in:
| Published in | Clinical immunology (Orlando, Fla.) Vol. 166-167; pp. 48 - 58 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1521-6616 1521-7035 1521-7035 |
| DOI | 10.1016/j.clim.2016.03.015 |
Cover
| Abstract | We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.
•A clinical trial of multipeptide cancer vaccine with cyclophosphamide was conducted.•Eighteen patients positive for HLA-A2402 with advanced solid tumors were enrolled.•Treatment was well tolerated without any adverse events above grade 3.•Vaccine-specific T cell responses were associated with longer survival. |
|---|---|
| AbstractList | We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.
•A clinical trial of multipeptide cancer vaccine with cyclophosphamide was conducted.•Eighteen patients positive for HLA-A2402 with advanced solid tumors were enrolled.•Treatment was well tolerated without any adverse events above grade 3.•Vaccine-specific T cell responses were associated with longer survival. We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies. We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies. Abstract We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies. |
| Author | Inoue, Hiroyuki Tamura, Kazuo Mizumoto, Kazuhiro Tanaka, Masao Morita, Masaru Maehara, Yoshihiko Fujii, Hiroshi Takahashi, Atsushi Nakamura, Yusuke Yoshida, Koji Marumoto, Tomotoshi Akashi, Koichi Tani, Kenzaburo Tsunoda, Takuya Tanaka, Yoshihiro Murahashi, Mutsunori Hijikata, Yasuki Yamada, Kazunari Baba, Eishi Okano, Shinji Nakanishi, Yoichi Okazaki, Toshihiko Takeda, Kazuyoshi Kishimoto, Junji Hirakawa, Masakazu |
| Author_xml | – sequence: 1 givenname: Mutsunori surname: Murahashi fullname: Murahashi, Mutsunori organization: Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan – sequence: 2 givenname: Yasuki surname: Hijikata fullname: Hijikata, Yasuki organization: Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan – sequence: 3 givenname: Kazunari surname: Yamada fullname: Yamada, Kazunari organization: Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan – sequence: 4 givenname: Yoshihiro surname: Tanaka fullname: Tanaka, Yoshihiro organization: Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan – sequence: 5 givenname: Junji surname: Kishimoto fullname: Kishimoto, Junji organization: Digital Medicine Initiative, Kyushu University, Fukuoka, Japan – sequence: 6 givenname: Hiroyuki surname: Inoue fullname: Inoue, Hiroyuki organization: Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan – sequence: 7 givenname: Tomotoshi surname: Marumoto fullname: Marumoto, Tomotoshi organization: Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan – sequence: 8 givenname: Atsushi surname: Takahashi fullname: Takahashi, Atsushi organization: Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan – sequence: 9 givenname: Toshihiko surname: Okazaki fullname: Okazaki, Toshihiko organization: Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan – sequence: 10 givenname: Kazuyoshi surname: Takeda fullname: Takeda, Kazuyoshi organization: Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan – sequence: 11 givenname: Masakazu surname: Hirakawa fullname: Hirakawa, Masakazu organization: Department of Radiology, Kyushu University Hospital, Fukuoka, Japan – sequence: 12 givenname: Hiroshi surname: Fujii fullname: Fujii, Hiroshi organization: Department of Pathology, Kyushu University, Fukuoka, Japan – sequence: 13 givenname: Shinji surname: Okano fullname: Okano, Shinji organization: Department of Pathology, Kyushu University, Fukuoka, Japan – sequence: 14 givenname: Masaru surname: Morita fullname: Morita, Masaru organization: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan – sequence: 15 givenname: Eishi surname: Baba fullname: Baba, Eishi organization: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan – sequence: 16 givenname: Kazuhiro surname: Mizumoto fullname: Mizumoto, Kazuhiro organization: Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan – sequence: 17 givenname: Yoshihiko surname: Maehara fullname: Maehara, Yoshihiko organization: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan – sequence: 18 givenname: Masao surname: Tanaka fullname: Tanaka, Masao organization: Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan – sequence: 19 givenname: Koichi surname: Akashi fullname: Akashi, Koichi organization: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan – sequence: 20 givenname: Yoichi surname: Nakanishi fullname: Nakanishi, Yoichi organization: Institute of Diseases of Chest, Kyushu University, Fukuoka, Japan – sequence: 21 givenname: Koji surname: Yoshida fullname: Yoshida, Koji organization: Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 22 givenname: Takuya surname: Tsunoda fullname: Tsunoda, Takuya organization: Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 23 givenname: Kazuo surname: Tamura fullname: Tamura, Kazuo organization: Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan – sequence: 24 givenname: Yusuke surname: Nakamura fullname: Nakamura, Yusuke organization: Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 25 givenname: Kenzaburo surname: Tani fullname: Tani, Kenzaburo email: k-tani@ims.u-tokyo.ac.jp organization: Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27072896$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl2L1DAUDbLifugf8EHy6EtrPpq0FRFk8WNhQUF9DunNLZOxbWrSGZl_b8rM-rDg7kvuDZxzQs45l-RsChMS8pKzkjOu32xLGPxYiryXTJaMqyfkgivBi5pJdXbateb6nFymtGWMKSH0M3IualaLptUXJHzb2IT0hmapyYMd6BJ9PkNPLe39HosZ58U7pGAnwEj3FsBP-RrGLk9H__hlQ-EAQ5g3Ic0bO65oP1Hr9ivF0RQG7-iyG0NMz8nT3g4JX5zmFfn56eOP6y_F7dfPN9cfbguoWrUUgqFtur4CbqEBDs5Zy7FykiNzleKuk_mPoEEx4ELJqtG1ZLpXsmMttE5ekddH3TmG3ztMixl9AhwGO2HYJcMb1uiWq5Y_Dq1blbHZrgx9dYLuuhGdmaMfbTyYOz8zQBwBEENKEft_EM7MGprZmjU0s4ZmmDQ5tExq7pHAL3bxYVqi9cPD1HdHKmYv9x6jSeBxdd1HhMW44B-mv79Hv6vBLzxg2oZdnHJKhpskDDPf10KtfeJa5i7VIgu8_b_AY6__BSi-2s0 |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2024_e41354 crossref_primary_10_7717_peerj_15615 crossref_primary_10_1002_psc_3596 crossref_primary_10_2217_imt_2016_0063 crossref_primary_10_4049_jimmunol_1701644 crossref_primary_10_1080_2162402X_2017_1313371 crossref_primary_10_1016_j_intimp_2023_111055 crossref_primary_10_3390_vaccines10010070 crossref_primary_10_1080_2162402X_2017_1386829 crossref_primary_10_1002_adhm_201801320 crossref_primary_10_1080_14712598_2017_1256388 crossref_primary_10_3389_fimmu_2022_942235 crossref_primary_10_1038_s41379_018_0074_y crossref_primary_10_2174_1389450120666190619121658 crossref_primary_10_3389_fimmu_2020_615240 crossref_primary_10_1111_cpr_13025 crossref_primary_10_1155_2019_5245034 crossref_primary_10_1080_07391102_2020_1797539 crossref_primary_10_1007_s10620_024_08774_2 crossref_primary_10_3389_fonc_2024_1427428 crossref_primary_10_1007_s00262_020_02619_3 crossref_primary_10_2174_0929867330666230426111157 crossref_primary_10_1002_anie_202008604 crossref_primary_10_1007_s10388_024_01072_w crossref_primary_10_1016_j_canlet_2018_08_028 crossref_primary_10_3389_fonc_2021_659964 crossref_primary_10_1371_journal_pone_0187878 crossref_primary_10_1007_s12032_023_02003_y crossref_primary_10_1186_s12885_018_4234_8 crossref_primary_10_1007_s00595_023_02773_y crossref_primary_10_1016_j_jconrel_2019_06_017 crossref_primary_10_1016_j_gastha_2023_09_007 crossref_primary_10_1002_ange_202008604 crossref_primary_10_1186_s40425_017_0270_1 crossref_primary_10_1186_s12967_016_1034_2 crossref_primary_10_3390_ph16071054 crossref_primary_10_3389_fcell_2021_664791 crossref_primary_10_3390_cells10113048 crossref_primary_10_1016_j_jconrel_2018_12_020 |
| Cites_doi | 10.1038/nm.2883 10.1097/COC.0b013e3182868ec8 10.1007/s00281-011-0245-0 10.1200/JCO.2008.16.6462 10.1182/blood-2004-06-2410 10.1093/annonc/mdv382 10.1002/jso.22108 10.1038/nrclinonc.2010.223 10.1186/1479-5876-12-63 10.1016/j.humimm.2009.05.006 10.1186/1479-5876-10-141 10.1007/s00066-010-2079-4 10.1186/1479-5876-9-17 10.4049/jimmunol.177.2.896 10.1056/NEJMoa071834 10.1158/1078-0432.CCR-12-3592 10.1111/j.0105-2896.2006.00391.x 10.1016/j.vaccine.2008.06.085 10.1073/pnas.0702257104 10.1016/j.humimm.2011.12.020 10.1056/NEJMoa1108188 10.1007/s00262-006-0225-8 10.1007/s00280-013-2106-0 10.1111/j.1349-7006.2009.01200.x 10.1158/1078-0432.CCR-07-0842 10.1016/j.humimm.2008.07.017 10.1038/nrclinonc.2013.46 10.1172/JCI35180 10.1038/nrclinonc.2014.111 10.1056/NEJMoa1105143 10.1038/nrclinonc.2011.116 10.1111/j.1349-7006.2007.00603.x 10.1038/nri778 10.1056/NEJMoa1501824 10.1158/0008-5472.CAN-06-3748 10.1016/j.humimm.2008.08.276 10.1016/j.smim.2010.03.004 10.1093/jjco/hys069 10.1016/j.vaccine.2007.06.067 10.1007/s00262-003-0480-x 10.1056/NEJMoa1200690 10.1038/sj.onc.1210466 10.1016/j.jamcollsurg.2003.10.005 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Inc. Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 |
| DOI | 10.1016/j.clim.2016.03.015 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1521-7035 |
| EndPage | 58 |
| ExternalDocumentID | 27072896 10_1016_j_clim_2016_03_015 S1521661616300572 1_s2_0_S1521661616300572 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABPPZ ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HX~ HZ~ IH2 IHE J1W K-O KOM L7B LG5 LUGTX M41 MO0 N9A O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSZ T5K X7M XPP Y6R Z5R ZGI ZMT ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG SSI AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD 7T5 H94 |
| ID | FETCH-LOGICAL-c495t-20ea8bf4c1ac8c1cddaa1e4d31e0d451db3703c6c50c12534867306f53b09c9d3 |
| IEDL.DBID | AIKHN |
| ISSN | 1521-6616 1521-7035 |
| IngestDate | Sat Sep 27 16:03:53 EDT 2025 Sun Sep 28 00:33:55 EDT 2025 Mon Jul 21 05:18:23 EDT 2025 Tue Jul 01 02:44:03 EDT 2025 Thu Apr 24 23:02:30 EDT 2025 Fri Feb 23 02:15:16 EST 2024 Tue Feb 25 20:03:50 EST 2025 Tue Aug 26 16:33:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | CPM Translational research Five-peptide cancer vaccine Cyclophosphamide OS TAA CTLs Treg cells PFS Regulatory T cells cytotoxic T lymphocytes tumor-associated antigen progression free survival regulatory T cells overall survival cyclophosphamide |
| Language | English |
| License | Copyright © 2016 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c495t-20ea8bf4c1ac8c1cddaa1e4d31e0d451db3703c6c50c12534867306f53b09c9d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 27072896 |
| PQID | 1795869896 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1808691591 proquest_miscellaneous_1795869896 pubmed_primary_27072896 crossref_primary_10_1016_j_clim_2016_03_015 crossref_citationtrail_10_1016_j_clim_2016_03_015 elsevier_sciencedirect_doi_10_1016_j_clim_2016_03_015 elsevier_clinicalkeyesjournals_1_s2_0_S1521661616300572 elsevier_clinicalkey_doi_10_1016_j_clim_2016_03_015 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-01 |
| PublicationDateYYYYMMDD | 2016-05-01 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical immunology (Orlando, Fla.) |
| PublicationTitleAlternate | Clin Immunol |
| PublicationYear | 2016 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Barve, Bender, Senzer (bb0045) 2008; 26 Nakagawa, Kanda, Kosugi, Ohashi, Suzuki, Hatakeyama (bb0210) 2004; 198 Walter, Weinschenk, Stenzl (bb0055) 2012; 18 Jarnicki, Lysaght, Todryk, Mills (bb0150) 2006; 177 Wang (bb0155) 2008; 69 Obara, Ohsawa, Kanehira (bb0100) 2012; 42 Suda, Tsunoda, Daigo (bb0095) 2007; 98 Aruga, Takeshita, Kotera (bb0115) 2013; 19 Klebanoff, Gattinoni, Restifo (bb0130) 2006; 211 Speiser, Romero (bb0035) 2010; 22 Shahabi, Postow, Tuck (bb0060) 2015; 38 Kanehira, Harada, Takata (bb0080) 2007; 26 Kanehira, Katagiri, Shimo (bb0075) 2007; 67 Yasuda, Tsuchiya, Okada (bb0110) 2012; 37 Svane, Pedersen, Nikolajsen (bb0205) 2008; 26 Kono, Mizukami, Daigo (bb0070) 2009; 100 Saadoun, Rosenzwajg, Joly (bb0180) 2011; 365 Melero, Gaudernack, Gerritsen (bb0010) 2014; 11 Suzuki, Ikeda, Okusaka (bb0195) 2013; 71 Rao, Han, Wang (bb0185) 2011; 9 Zitvogel, Kepp, Kroemer (bb0230) 2011; 8 Vatner, Cooper, Vanpouille-Box (bb0220) 2014; 28 Kaech, Wherry, Ahmed (bb0125) 2002; 2 Traverso, Fenoglio, Negrini (bb0170) 2012; 73 Finke, Wentworth, Blumenstein (bb0005) 2007; 25 Joosten, Ottenhoff (bb0165) 2008; 69 Ghiringhelli, Menard, Puig (bb0050) 2007; 56 Okada, Fujiwara, Nakamura (bb0090) 2012; 105 Allred, Harvey, Berardo (bb0120) 1998; 11 Sistigu, Viaud, Chaput (bb0135) 2011; 33 Garon, Rizvi, Hui (bb0020) 2015; 372 Topalian, Hodi, Brahmer (bb0015) 2012; 366 Kono, Iinuma, Akutsu (bb0105) 2012; 10 Rosenberg (bb0025) 2011; 8 Singh-Jasuja, Emmerich, Rammensee (bb0040) 2004; 53 Keicho, Itoyama, Kashiwase (bb0065) 2009; 70 Zitvogel, Apetoh, Ghiringhelli (bb0225) 2008; 118 Joosten, van Meijgaarden, Savage (bb0160) 2007; 104 Kiniwa, Miyahara, Wang (bb0145) 2007; 13 Lutsiak, Semnani, De Pascalis (bb0140) 2005; 105 Jonker, O'Callaghan, Karapetis (bb0190) 2007; 357 BioGPS Koreth, Matsuoka, Kim (bb0175) 2011; 365 Hazama, Nakamura, Takenouchi (bb0200) 2014; 12 2016. Martin, Coukos, Holt (bb0235) 2015; 26 Mizumoto, Sugahara, Nakayama (bb0215) 2010; 186 Kochenderfer, Rosenberg (bb0030) 2013; 10 Kanehira (10.1016/j.clim.2016.03.015_bb0080) 2007; 26 Saadoun (10.1016/j.clim.2016.03.015_bb0180) 2011; 365 Barve (10.1016/j.clim.2016.03.015_bb0045) 2008; 26 10.1016/j.clim.2016.03.015_bb0085 Traverso (10.1016/j.clim.2016.03.015_bb0170) 2012; 73 Wang (10.1016/j.clim.2016.03.015_bb0155) 2008; 69 Svane (10.1016/j.clim.2016.03.015_bb0205) 2008; 26 Zitvogel (10.1016/j.clim.2016.03.015_bb0225) 2008; 118 Speiser (10.1016/j.clim.2016.03.015_bb0035) 2010; 22 Allred (10.1016/j.clim.2016.03.015_bb0120) 1998; 11 Joosten (10.1016/j.clim.2016.03.015_bb0160) 2007; 104 Kono (10.1016/j.clim.2016.03.015_bb0070) 2009; 100 Aruga (10.1016/j.clim.2016.03.015_bb0115) 2013; 19 Singh-Jasuja (10.1016/j.clim.2016.03.015_bb0040) 2004; 53 Suda (10.1016/j.clim.2016.03.015_bb0095) 2007; 98 Hazama (10.1016/j.clim.2016.03.015_bb0200) 2014; 12 Keicho (10.1016/j.clim.2016.03.015_bb0065) 2009; 70 Okada (10.1016/j.clim.2016.03.015_bb0090) 2012; 105 Garon (10.1016/j.clim.2016.03.015_bb0020) 2015; 372 Zitvogel (10.1016/j.clim.2016.03.015_bb0230) 2011; 8 Jonker (10.1016/j.clim.2016.03.015_bb0190) 2007; 357 Walter (10.1016/j.clim.2016.03.015_bb0055) 2012; 18 Klebanoff (10.1016/j.clim.2016.03.015_bb0130) 2006; 211 Kochenderfer (10.1016/j.clim.2016.03.015_bb0030) 2013; 10 Rosenberg (10.1016/j.clim.2016.03.015_bb0025) 2011; 8 Jarnicki (10.1016/j.clim.2016.03.015_bb0150) 2006; 177 Topalian (10.1016/j.clim.2016.03.015_bb0015) 2012; 366 Kaech (10.1016/j.clim.2016.03.015_bb0125) 2002; 2 Martin (10.1016/j.clim.2016.03.015_bb0235) 2015; 26 Kanehira (10.1016/j.clim.2016.03.015_bb0075) 2007; 67 Lutsiak (10.1016/j.clim.2016.03.015_bb0140) 2005; 105 Nakagawa (10.1016/j.clim.2016.03.015_bb0210) 2004; 198 Kono (10.1016/j.clim.2016.03.015_bb0105) 2012; 10 Vatner (10.1016/j.clim.2016.03.015_bb0220) 2014; 28 Melero (10.1016/j.clim.2016.03.015_bb0010) 2014; 11 Kiniwa (10.1016/j.clim.2016.03.015_bb0145) 2007; 13 Suzuki (10.1016/j.clim.2016.03.015_bb0195) 2013; 71 Finke (10.1016/j.clim.2016.03.015_bb0005) 2007; 25 Sistigu (10.1016/j.clim.2016.03.015_bb0135) 2011; 33 Ghiringhelli (10.1016/j.clim.2016.03.015_bb0050) 2007; 56 Mizumoto (10.1016/j.clim.2016.03.015_bb0215) 2010; 186 Obara (10.1016/j.clim.2016.03.015_bb0100) 2012; 42 Yasuda (10.1016/j.clim.2016.03.015_bb0110) 2012; 37 Rao (10.1016/j.clim.2016.03.015_bb0185) 2011; 9 Shahabi (10.1016/j.clim.2016.03.015_bb0060) 2015; 38 Koreth (10.1016/j.clim.2016.03.015_bb0175) 2011; 365 Joosten (10.1016/j.clim.2016.03.015_bb0165) 2008; 69 |
| References_xml | – volume: 69 start-page: 811 year: 2008 end-page: 814 ident: bb0155 article-title: CD8 publication-title: Hum. Immunol. – volume: 28 start-page: 325 year: 2014 ident: bb0220 article-title: Combinations of immunotherapy and radiation in cancer therapy publication-title: Front Oncol. – volume: 8 start-page: 577 year: 2011 end-page: 585 ident: bb0025 article-title: Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know publication-title: Nat. Rev. Clin. Oncol. – reference: >, 2016. – volume: 70 start-page: 527 year: 2009 end-page: 531 ident: bb0065 article-title: Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population publication-title: Hum. Immunol. – volume: 211 start-page: 214 year: 2006 end-page: 224 ident: bb0130 article-title: CD8 publication-title: Immunol. Rev. – volume: 22 start-page: 144 year: 2010 end-page: 154 ident: bb0035 article-title: Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity publication-title: Semin. Immunol. – volume: 13 start-page: 6947 year: 2007 end-page: 6958 ident: bb0145 article-title: CD8 publication-title: Clin. Cancer Res. – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: bb0015 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N. Engl. J. Med. – volume: 10 start-page: 267 year: 2013 end-page: 276 ident: bb0030 article-title: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors publication-title: Nat. Rev. Clin. Oncol. – volume: 105 start-page: 2862 year: 2005 end-page: 2868 ident: bb0140 article-title: Inhibition of CD4(+)25 publication-title: Blood – volume: 118 start-page: 1991 year: 2008 end-page: 2001 ident: bb0225 article-title: The anticancer immune response: indispensable for therapeutic success? publication-title: J. Clin. Invest. – volume: 25 start-page: B97 year: 2007 end-page: B109 ident: bb0005 article-title: Lessons from randomized phase III studies with active cancer immunotherapies—outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC) publication-title: Vaccine – volume: 11 start-page: 509 year: 2014 end-page: 524 ident: bb0010 article-title: Therapeutic vaccines for cancer: an overview of clinical trials publication-title: Nat. Rev. Clin. Oncol. – volume: 37 start-page: 57 year: 2012 end-page: 61 ident: bb0110 article-title: Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report publication-title: Tokai J. Exp. Clin. Med. – volume: 11 start-page: 155 year: 1998 end-page: 168 ident: bb0120 article-title: Prognostic and predictive factors in breast cancer by immunohistochemical analysis publication-title: Mod. Pathol. – volume: 372 start-page: 2018 year: 2015 end-page: 2028 ident: bb0020 article-title: Pembrolizumab for the treatment of non-small-cell lung cancer publication-title: N. Engl. J. Med. – volume: 98 start-page: 1803 year: 2007 end-page: 1808 ident: bb0095 article-title: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy publication-title: Cancer Sci. – volume: 53 start-page: 187 year: 2004 end-page: 195 ident: bb0040 article-title: The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy publication-title: Cancer Immunol. Immunother. – volume: 2 start-page: 251 year: 2002 end-page: 262 ident: bb0125 article-title: Effector and memory T-cell differentiation: implications for vaccine development publication-title: Nat. Rev. Immunol. – volume: 18 start-page: 1254 year: 2012 end-page: 1261 ident: bb0055 article-title: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival publication-title: Nat. Med. – volume: 26 start-page: 4418 year: 2008 end-page: 4425 ident: bb0045 article-title: Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer publication-title: J. Clin. Oncol. – volume: 12 start-page: 63 year: 2014 ident: bb0200 article-title: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunologicalresponse, and clinical outcome publication-title: J. Transl. Med. – volume: 26 start-page: 4716 year: 2008 end-page: 4724 ident: bb0205 article-title: Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2 publication-title: Vaccine – volume: 42 start-page: 591 year: 2012 end-page: 600 ident: bb0100 article-title: Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for Bladder Cancer publication-title: Jpn. J. Clin. Oncol. – reference: BioGPS < – volume: 26 start-page: 6448 year: 2007 end-page: 6455 ident: bb0080 article-title: Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis publication-title: Oncogene – volume: 104 start-page: 8029 year: 2007 end-page: 8034 ident: bb0160 article-title: Identification of a human CD8 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 9 start-page: 17 year: 2011 ident: bb0185 article-title: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review publication-title: J. Transl. Med. – volume: 38 start-page: 90 year: 2015 end-page: 97 ident: bb0060 article-title: Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy publication-title: Am. J. Clin. Oncol. – volume: 100 start-page: 1502 year: 2009 end-page: 1509 ident: bb0070 article-title: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer publication-title: Cancer Sci. – volume: 19 start-page: 2224 year: 2013 end-page: 2231 ident: bb0115 article-title: Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer publication-title: Clin. Cancer Res. – volume: 177 start-page: 896 year: 2006 end-page: 904 ident: bb0150 article-title: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4 publication-title: J. Immunol. – volume: 67 start-page: 3276 year: 2007 end-page: 3285 ident: bb0075 article-title: Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer publication-title: Cancer Res. – volume: 105 start-page: 780 year: 2012 end-page: 785 ident: bb0090 article-title: Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma publication-title: J. Surg. Oncol. – volume: 33 start-page: 369 year: 2011 end-page: 383 ident: bb0135 article-title: Immunomodulatory effects of cyclophosphamide and implementations for vaccine design publication-title: Semin. Immunopathol. – volume: 69 start-page: 760 year: 2008 end-page: 770 ident: bb0165 article-title: Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination publication-title: Hum. Immunol. – volume: 26 start-page: 2367 year: 2015 end-page: 2374 ident: bb0235 article-title: Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era publication-title: Ann. Oncol. – volume: 186 start-page: 482 year: 2010 end-page: 488 ident: bb0215 article-title: Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer publication-title: Strahlenther. Onkol. – volume: 365 start-page: 2055 year: 2011 end-page: 2066 ident: bb0175 article-title: Interleukin-2 and regulatory T cells in graft-versus-host disease publication-title: N. Engl. J. Med. – volume: 73 start-page: 207 year: 2012 end-page: 213 ident: bb0170 article-title: Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells publication-title: Hum. Immunol. – volume: 10 start-page: 141 year: 2012 ident: bb0105 article-title: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens publication-title: J. Transl. Med. – volume: 357 start-page: 2040 year: 2007 end-page: 2048 ident: bb0190 article-title: Cetuximab for the treatment of colorectal cancer publication-title: N. Engl. J. Med. – volume: 198 start-page: 205 year: 2004 end-page: 211 ident: bb0210 article-title: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy publication-title: J. Am. Coll. Surg. – volume: 71 start-page: 1141 year: 2013 end-page: 1146 ident: bb0195 article-title: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer publication-title: Cancer Chemother. Pharmacol. – volume: 8 start-page: 151 year: 2011 end-page: 160 ident: bb0230 article-title: Immune parameters affecting the efficacy of chemotherapeutic regimens publication-title: Nat. Rev. Clin. Oncol. – volume: 56 start-page: 641 year: 2007 end-page: 648 ident: bb0050 article-title: Metronomic cyclophosphamide regimen selectively depletes CD4 publication-title: Cancer Immunol. Immunother. – volume: 365 start-page: 2067 year: 2011 end-page: 2077 ident: bb0180 article-title: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis publication-title: N. Engl. J. Med. – volume: 18 start-page: 1254 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0055 article-title: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival publication-title: Nat. Med. doi: 10.1038/nm.2883 – volume: 38 start-page: 90 year: 2015 ident: 10.1016/j.clim.2016.03.015_bb0060 article-title: Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy publication-title: Am. J. Clin. Oncol. doi: 10.1097/COC.0b013e3182868ec8 – volume: 33 start-page: 369 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0135 article-title: Immunomodulatory effects of cyclophosphamide and implementations for vaccine design publication-title: Semin. Immunopathol. doi: 10.1007/s00281-011-0245-0 – volume: 26 start-page: 4418 year: 2008 ident: 10.1016/j.clim.2016.03.015_bb0045 article-title: Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.16.6462 – volume: 105 start-page: 2862 year: 2005 ident: 10.1016/j.clim.2016.03.015_bb0140 article-title: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide publication-title: Blood doi: 10.1182/blood-2004-06-2410 – volume: 26 start-page: 2367 year: 2015 ident: 10.1016/j.clim.2016.03.015_bb0235 article-title: Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv382 – volume: 105 start-page: 780 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0090 article-title: Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma publication-title: J. Surg. Oncol. doi: 10.1002/jso.22108 – volume: 8 start-page: 151 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0230 article-title: Immune parameters affecting the efficacy of chemotherapeutic regimens publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2010.223 – volume: 11 start-page: 155 year: 1998 ident: 10.1016/j.clim.2016.03.015_bb0120 article-title: Prognostic and predictive factors in breast cancer by immunohistochemical analysis publication-title: Mod. Pathol. – volume: 12 start-page: 63 year: 2014 ident: 10.1016/j.clim.2016.03.015_bb0200 article-title: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunologicalresponse, and clinical outcome publication-title: J. Transl. Med. doi: 10.1186/1479-5876-12-63 – volume: 70 start-page: 527 year: 2009 ident: 10.1016/j.clim.2016.03.015_bb0065 article-title: Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population publication-title: Hum. Immunol. doi: 10.1016/j.humimm.2009.05.006 – volume: 10 start-page: 141 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0105 article-title: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens publication-title: J. Transl. Med. doi: 10.1186/1479-5876-10-141 – volume: 186 start-page: 482 year: 2010 ident: 10.1016/j.clim.2016.03.015_bb0215 article-title: Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer publication-title: Strahlenther. Onkol. doi: 10.1007/s00066-010-2079-4 – volume: 9 start-page: 17 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0185 article-title: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review publication-title: J. Transl. Med. doi: 10.1186/1479-5876-9-17 – volume: 177 start-page: 896 year: 2006 ident: 10.1016/j.clim.2016.03.015_bb0150 article-title: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.177.2.896 – volume: 28 start-page: 325 year: 2014 ident: 10.1016/j.clim.2016.03.015_bb0220 article-title: Combinations of immunotherapy and radiation in cancer therapy publication-title: Front Oncol. – volume: 357 start-page: 2040 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0190 article-title: Cetuximab for the treatment of colorectal cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa071834 – volume: 19 start-page: 2224 year: 2013 ident: 10.1016/j.clim.2016.03.015_bb0115 article-title: Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-3592 – volume: 211 start-page: 214 year: 2006 ident: 10.1016/j.clim.2016.03.015_bb0130 article-title: CD8+ T-cell memory in tumor immunology and immunotherapy publication-title: Immunol. Rev. doi: 10.1111/j.0105-2896.2006.00391.x – volume: 26 start-page: 4716 year: 2008 ident: 10.1016/j.clim.2016.03.015_bb0205 article-title: Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.06.085 – volume: 104 start-page: 8029 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0160 article-title: Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0702257104 – volume: 73 start-page: 207 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0170 article-title: Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells publication-title: Hum. Immunol. doi: 10.1016/j.humimm.2011.12.020 – volume: 365 start-page: 2055 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0175 article-title: Interleukin-2 and regulatory T cells in graft-versus-host disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1108188 – volume: 56 start-page: 641 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0050 article-title: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-006-0225-8 – volume: 71 start-page: 1141 year: 2013 ident: 10.1016/j.clim.2016.03.015_bb0195 article-title: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-013-2106-0 – volume: 100 start-page: 1502 year: 2009 ident: 10.1016/j.clim.2016.03.015_bb0070 article-title: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2009.01200.x – volume: 13 start-page: 6947 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0145 article-title: CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-0842 – volume: 69 start-page: 760 year: 2008 ident: 10.1016/j.clim.2016.03.015_bb0165 article-title: Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination publication-title: Hum. Immunol. doi: 10.1016/j.humimm.2008.07.017 – volume: 10 start-page: 267 year: 2013 ident: 10.1016/j.clim.2016.03.015_bb0030 article-title: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2013.46 – ident: 10.1016/j.clim.2016.03.015_bb0085 – volume: 118 start-page: 1991 year: 2008 ident: 10.1016/j.clim.2016.03.015_bb0225 article-title: The anticancer immune response: indispensable for therapeutic success? publication-title: J. Clin. Invest. doi: 10.1172/JCI35180 – volume: 11 start-page: 509 year: 2014 ident: 10.1016/j.clim.2016.03.015_bb0010 article-title: Therapeutic vaccines for cancer: an overview of clinical trials publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2014.111 – volume: 365 start-page: 2067 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0180 article-title: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1105143 – volume: 8 start-page: 577 year: 2011 ident: 10.1016/j.clim.2016.03.015_bb0025 article-title: Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2011.116 – volume: 98 start-page: 1803 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0095 article-title: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2007.00603.x – volume: 2 start-page: 251 year: 2002 ident: 10.1016/j.clim.2016.03.015_bb0125 article-title: Effector and memory T-cell differentiation: implications for vaccine development publication-title: Nat. Rev. Immunol. doi: 10.1038/nri778 – volume: 37 start-page: 57 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0110 article-title: Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report publication-title: Tokai J. Exp. Clin. Med. – volume: 372 start-page: 2018 year: 2015 ident: 10.1016/j.clim.2016.03.015_bb0020 article-title: Pembrolizumab for the treatment of non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1501824 – volume: 67 start-page: 3276 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0075 article-title: Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-3748 – volume: 69 start-page: 811 year: 2008 ident: 10.1016/j.clim.2016.03.015_bb0155 article-title: CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer publication-title: Hum. Immunol. doi: 10.1016/j.humimm.2008.08.276 – volume: 22 start-page: 144 year: 2010 ident: 10.1016/j.clim.2016.03.015_bb0035 article-title: Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity publication-title: Semin. Immunol. doi: 10.1016/j.smim.2010.03.004 – volume: 42 start-page: 591 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0100 article-title: Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for Bladder Cancer publication-title: Jpn. J. Clin. Oncol. doi: 10.1093/jjco/hys069 – volume: 25 start-page: B97 issue: Suppl. 2 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0005 article-title: Lessons from randomized phase III studies with active cancer immunotherapies—outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC) publication-title: Vaccine doi: 10.1016/j.vaccine.2007.06.067 – volume: 53 start-page: 187 year: 2004 ident: 10.1016/j.clim.2016.03.015_bb0040 article-title: The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-003-0480-x – volume: 366 start-page: 2443 year: 2012 ident: 10.1016/j.clim.2016.03.015_bb0015 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200690 – volume: 26 start-page: 6448 year: 2007 ident: 10.1016/j.clim.2016.03.015_bb0080 article-title: Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis publication-title: Oncogene doi: 10.1038/sj.onc.1210466 – volume: 198 start-page: 205 year: 2004 ident: 10.1016/j.clim.2016.03.015_bb0210 article-title: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy publication-title: J. Am. Coll. Surg. doi: 10.1016/j.jamcollsurg.2003.10.005 |
| SSID | ssj0005226 |
| Score | 2.3920486 |
| Snippet | We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with... Abstract We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 48 |
| SubjectTerms | Adult Aged Aged, 80 and over Allergy and Immunology Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - immunology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Vaccines - administration & dosage Cancer Vaccines - adverse effects Cancer Vaccines - immunology Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - immunology Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Cyclophosphamide - immunology Dose-Response Relationship, Drug Drug Administration Schedule Epitopes - administration & dosage Epitopes - immunology Female Five-peptide cancer vaccine HLA-A24 Antigen - genetics HLA-A24 Antigen - immunology Humans Kaplan-Meier Estimate Leukopenia - chemically induced Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Male Middle Aged Neoplasms - drug therapy Neoplasms - genetics Neoplasms - immunology Peptides - administration & dosage Peptides - immunology Regulatory T cells Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - immunology T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Translational research Treatment Outcome Vaccines, Subunit - administration & dosage Vaccines, Subunit - adverse effects Vaccines, Subunit - immunology |
| Title | Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1521661616300572 https://www.clinicalkey.es/playcontent/1-s2.0-S1521661616300572 https://dx.doi.org/10.1016/j.clim.2016.03.015 https://www.ncbi.nlm.nih.gov/pubmed/27072896 https://www.proquest.com/docview/1795869896 https://www.proquest.com/docview/1808691591 |
| Volume | 166-167 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbpBkovpelz2yao0Ftx17Lk1zGEhE1LQqEN5Cbkkcw6bGyz3i300t_eGVteWpJuofhkM4PEp9HMyJoHY-8hSgqbOwhcXqpAFbkJshhkoFSZorkVZVRSNvLFZTK_Up-u4-s9djLmwlBYpdf9g07vtbX_MvNoztqqmn0ly4PWBR8quZ6iHt6P0NpnE7Z_fP55fvlbpEffdY3oA2LwuTNDmBcsK0pIF0lf65S6495vn_7mf_Z26OwJe-wdSH48zPGA7bn6KXt44a_In7HmywINEz_nY84j7xtz8Kbkhpeo24KWAlms40ALvuLfDRAnRwTwlOwsp1-zHH7AsmkXTdcuzC1RVzUf4wU4ymtl-Xpz26y65-zq7PTbyTzwXRUCwMPQGreFM1lRKhAGMhBgrTHCKSuFC62KhS0kagFIIA4BvR9JJfnwXFHGsghzyK18wSZ1U7tXjOdpISIBWYynNmWpQqU0kJYmNjIpCqmmTIxYavAlx6nzxVKPsWU3mvDXhL8OpUb8p-zDlqcdCm7spJbjEukRVlR-Gu3BTq70Pi7X-f3baaG7SIf6joxNWbzl_ENM_zniu1F-NO5fupQxtWs2OFKaxxl18Ux20CC0SY6Op5iyl4PwbbGJ0jBF-JPX_zmzN-wRvQ0xnG_ZZL3auEP0s9bFEXvw8ac48rvpF9d2Jio |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBclhW0vY9_LPjXY2zCxIvnrsZSVZG3CYC30TcgnmbiktomTwf773dly2FiXwfCbfYfET6e7k3UfjH2EaZzbzEHgskIFKs9MkEYgA6WKBM2tKKYFZSMvlvHsSn25jq6P2OmQC0NhlV739zq909b-zcSjOWnKcvKNLA9aF3yo5HqCevhYUVPrETs-mZ_Plr9EenRd14g-IAafO9OHecG6pIR0EXe1Tqk77t326W_-Z2eHzh6xh96B5Cf9HB-zI1c9YfcW_or8Kau_rtAw8Tkfch5515iD1wU3vEDdFjQUyGIdB1rwDf9ugDg5IoCnZGc5_Zrl8APWdbOq22Zlbom6rPgQL8BRXkvLt7vbetM-Y1dnny9PZ4HvqhAAHoa2uC2cSfNCgTCQggBrjRFOWSlcaFUkbC5RC0AMUQjo_UgqyYfniiKSeZhBZuVzNqrqyr1kPEtyMRWQRnhqU5YqVEoDSWEiI-M8l2rMxIClBl9ynDpfrPUQW3ajCX9N-OtQasR_zD7teZq-4MZBajkskR5gReWn0R4c5Eru4nKt37-tFrqd6lD_IWNjFu05fxPTf474YZAfjfuXLmVM5eodjpRkUUpdPOMDNAhtnKHjKcbsRS98e2ymSZgg_PGr_5zZe3Z_drm40Bfz5flr9oC-9PGcb9hou9m5t-hzbfN3fk_9BME1KBA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I+clinical+trial+of+a+five-peptide+cancer+vaccine+combined+with+cyclophosphamide+in+advanced+solid+tumors&rft.jtitle=Clinical+immunology+%28Orlando%2C+Fla.%29&rft.au=Murahashi%2C+Mutsunori&rft.au=Hijikata%2C+Yasuki&rft.au=Yamada%2C+Kazunari&rft.au=Tanaka%2C+Yoshihiro&rft.date=2016-05-01&rft.pub=Elsevier+Inc&rft.issn=1521-6616&rft.volume=166-167&rft.spage=48&rft.epage=58&rft_id=info:doi/10.1016%2Fj.clim.2016.03.015&rft.externalDocID=S1521661616300572 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15216616%2FS1521661616X00058%2Fcov150h.gif |